Andrew Pieper

Title: Innovations of Andrew Pieper in Neurotoxicity Treatment

Introduction

Andrew Pieper is an accomplished inventor based in Baltimore, MD. He has made significant contributions to the field of neurotoxicity treatment through his innovative research and patent.

Latest Patents

Andrew Pieper holds a patent for a method of using selective PARP inhibitors to prevent or treat neurotoxicity. This patent addresses neutral tissue damage resulting from ischemia and reperfusion injury or neurodegenerative diseases. The invention involves administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose) polymerase. These inhibitors can be delivered through various methods, including intravenous, intraperitoneal, intramuscular, intraventricular, or oral administration. They can be provided in the form of capsules or tablets containing single or divided doses, or as sterile solutions, suspensions, or emulsions.

Career Highlights

Andrew Pieper is affiliated with The Johns Hopkins University, where he continues to advance his research in neurotoxicity and related fields. His work has garnered attention for its potential to improve treatment options for patients suffering from neurodegenerative diseases.

Collaborations

Some of his notable coworkers include Mikael J Eliasson and Kenji Sampei, who have collaborated with him on various research projects.

Conclusion

Andrew Pieper's innovative work in the field of neurotoxicity treatment highlights the importance of research and development in addressing complex medical challenges. His contributions through his patent demonstrate a commitment to improving patient outcomes and advancing scientific knowledge.